



September 9, 2019

Shin Nippon Biomedical Laboratories, Ltd.
(Tokyo Stock Exchange First Section Code: 2395)

Representative: Ryoichi Nagata, Chairman and President

Contact: Shinji Nitanda, Senior Vice-President
(TEL : +81-3-5565-5001)

Gemseki Inc. selected as one of the “Top 10 Drug Discovery Consulting/Services Companies in APAC 2019” by Pharma Tech Outlook

Gemseki Inc.¹⁾ (President and CEO: Hideyuki Hirama), a subsidiary of SNBL Ltd., has been selected as one of the “Top 10 Drug Discovery Consulting/Services Companies in APAC 2019” by Pharma Tech Outlook²⁾, a well-subscribed monthly magazine that focuses on the life science industry. Gemseki has been selected for its innovative business model, unique perspective, and highly active business and is featured as the cover story in the September 2019, Drug Discovery Service Special Edition.

Gemseki launched its business in October, 2017 and facilitates licensing and partnering in the life science industry. This is achieved efficiently and effectively through its global website, the Drug Candidate Marketplace (<https://www.gemseki.com/en/drugcandidatemarket>), while its experienced staff members provide in-depth support for clients. Gemseki only charges fees when a deal is closed. Thanks to this innovative approach, more than 100 drug candidates and technologies from various regions of the world have been registered in the Drug Candidate Marketplace, despite Gemseki’s short history of less than 2 years.

Dr. Ryoichi Nagata, Chairman and CEO of SNBL and Chairman of Gemseki, says, “Gemseki has built an unprecedented innovative business model and is aiming to become indispensable to the industry. Together with Gemseki, SNBL Group hopes to continue contributing to innovation in the pharmaceutical and biotech industry.” Hideyuki Hirama, President and CEO of Gemseki, adds, “It is a great honor to be selected by Pharma Tech Outlook panel of industry experts and editors. Gemseki will continue to endeavor in helping patients by finding the best partners for our clients, bringing better pharmaceutical products to the market sooner.”

1) Gemseki Inc. (<https://www.gemseki.com/en/>)

Gemseki launched in October 2017 as a subsidiary of SNBL, the largest preclinical CRO in Japan. Gemseki facilitates licensing and partnering activities through its efficient and effective Drug Candidate Marketplace (<https://www.gemseki.com/en/drugcandidatemarket>).

2) Pharma Tech Outlook is an enterprise technology print magazine that is the go-to resource for senior-level medical experts and decision-makers to learn and share their experiences with products/services, technologies, and Pharma technology trends. Pharma Tech Outlook provides a knowledge platform to senior executives to share their experiences and learn from each other along with short but in-depth profiles about top providers in the pharma industry.